Udaya Kompella
Concepts (714)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Drug Delivery Systems | 39 | 2021 | 296 | 8.400 |
Why?
| Nanoparticles | 33 | 2022 | 313 | 5.690 |
Why?
| Retina | 27 | 2020 | 263 | 4.770 |
Why?
| Sulfonamides | 17 | 2017 | 445 | 3.410 |
Why?
| Eye Diseases | 11 | 2021 | 76 | 3.350 |
Why?
| Choroid | 14 | 2020 | 47 | 2.950 |
Why?
| Pyrazoles | 14 | 2014 | 364 | 2.630 |
Why?
| Eye | 12 | 2017 | 101 | 2.550 |
Why?
| Drug Carriers | 14 | 2019 | 112 | 2.320 |
Why?
| Triptorelin Pamoate | 14 | 2009 | 19 | 2.290 |
Why?
| Vascular Endothelial Growth Factor A | 23 | 2017 | 498 | 2.250 |
Why?
| Polyglycolic Acid | 16 | 2015 | 43 | 2.150 |
Why?
| Lactic Acid | 17 | 2015 | 275 | 2.080 |
Why?
| Delayed-Action Preparations | 17 | 2020 | 159 | 2.040 |
Why?
| Ophthalmic Solutions | 11 | 2017 | 66 | 2.030 |
Why?
| Budesonide | 8 | 2020 | 87 | 1.910 |
Why?
| Pharmaceutical Preparations | 8 | 2022 | 168 | 1.850 |
Why?
| Gene Transfer Techniques | 8 | 2014 | 147 | 1.830 |
Why?
| Pigment Epithelium of Eye | 11 | 2012 | 34 | 1.810 |
Why?
| Sclera | 9 | 2012 | 35 | 1.750 |
Why?
| Animals | 116 | 2023 | 31761 | 1.740 |
Why?
| Diabetic Retinopathy | 8 | 2018 | 149 | 1.700 |
Why?
| Diabetes Mellitus, Experimental | 9 | 2018 | 162 | 1.700 |
Why?
| Particle Size | 16 | 2020 | 317 | 1.670 |
Why?
| Rabbits | 28 | 2022 | 736 | 1.480 |
Why?
| Conjunctiva | 14 | 2009 | 51 | 1.470 |
Why?
| Enzyme Inhibitors | 10 | 2011 | 751 | 1.450 |
Why?
| Tandem Mass Spectrometry | 8 | 2022 | 413 | 1.440 |
Why?
| Retinal Pigment Epithelium | 7 | 2013 | 58 | 1.420 |
Why?
| Nanostructures | 4 | 2019 | 96 | 1.410 |
Why?
| Blood-Retinal Barrier | 6 | 2013 | 13 | 1.400 |
Why?
| Rats | 34 | 2020 | 4943 | 1.370 |
Why?
| Dexamethasone | 4 | 2020 | 317 | 1.350 |
Why?
| Sulfones | 6 | 2012 | 97 | 1.340 |
Why?
| Vitreous Body | 13 | 2020 | 101 | 1.340 |
Why?
| Cyclooxygenase Inhibitors | 6 | 2008 | 72 | 1.310 |
Why?
| Rats, Sprague-Dawley | 26 | 2020 | 2209 | 1.290 |
Why?
| Drug Compounding | 6 | 2020 | 89 | 1.250 |
Why?
| Capillary Permeability | 6 | 2011 | 135 | 1.250 |
Why?
| Melanins | 4 | 2012 | 17 | 1.240 |
Why?
| Polymers | 8 | 2013 | 447 | 1.160 |
Why?
| Anti-Inflammatory Agents | 6 | 2020 | 450 | 1.140 |
Why?
| Glucocorticoids | 6 | 2021 | 532 | 1.130 |
Why?
| Cattle | 18 | 2021 | 921 | 1.130 |
Why?
| Receptors, LHRH | 5 | 2009 | 14 | 1.100 |
Why?
| Glycine | 6 | 2009 | 152 | 1.100 |
Why?
| Aldehyde Reductase | 5 | 2007 | 24 | 1.080 |
Why?
| Cornea | 10 | 2015 | 107 | 1.050 |
Why?
| RNA, Small Interfering | 5 | 2017 | 543 | 1.030 |
Why?
| Nanotechnology | 5 | 2019 | 113 | 1.020 |
Why?
| Nasal Mucosa | 6 | 2009 | 93 | 1.010 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 6 | 2012 | 299 | 1.010 |
Why?
| Celecoxib | 14 | 2014 | 38 | 0.980 |
Why?
| Intercellular Signaling Peptides and Proteins | 5 | 2013 | 350 | 0.970 |
Why?
| Epithelial Cells | 8 | 2016 | 955 | 0.960 |
Why?
| Angiogenesis Inhibitors | 8 | 2017 | 215 | 0.940 |
Why?
| alpha-Crystallin B Chain | 2 | 2022 | 18 | 0.930 |
Why?
| Retinal Degeneration | 3 | 2020 | 30 | 0.910 |
Why?
| Dendrimers | 4 | 2012 | 13 | 0.890 |
Why?
| Chromatography, Liquid | 7 | 2022 | 348 | 0.890 |
Why?
| Tomography, Optical Coherence | 2 | 2021 | 130 | 0.870 |
Why?
| Gonadotropin-Releasing Hormone | 5 | 2006 | 188 | 0.860 |
Why?
| Intraocular Pressure | 4 | 2020 | 276 | 0.840 |
Why?
| Choroidal Neovascularization | 6 | 2017 | 44 | 0.840 |
Why?
| Cyprinidae | 1 | 2022 | 19 | 0.830 |
Why?
| Cyclooxygenase 2 Inhibitors | 6 | 2014 | 20 | 0.830 |
Why?
| Sotalol | 1 | 2022 | 4 | 0.830 |
Why?
| Insulins | 1 | 2022 | 32 | 0.800 |
Why?
| Awards and Prizes | 1 | 2022 | 56 | 0.790 |
Why?
| Tissue Distribution | 10 | 2019 | 285 | 0.780 |
Why?
| Neuroprotective Agents | 1 | 2022 | 105 | 0.780 |
Why?
| Lymphocyte Function-Associated Antigen-1 | 2 | 2012 | 34 | 0.780 |
Why?
| Ophthalmoscopes | 1 | 2021 | 2 | 0.770 |
Why?
| Viscosity | 2 | 2020 | 81 | 0.770 |
Why?
| Glaucoma | 4 | 2020 | 202 | 0.770 |
Why?
| Administration, Topical | 10 | 2020 | 139 | 0.760 |
Why?
| Administration, Ophthalmic | 8 | 2021 | 14 | 0.750 |
Why?
| Peptides | 5 | 2022 | 848 | 0.740 |
Why?
| Molecular Chaperones | 3 | 2022 | 157 | 0.720 |
Why?
| Water | 3 | 2019 | 399 | 0.720 |
Why?
| Lens, Crystalline | 4 | 2011 | 96 | 0.720 |
Why?
| Intravitreal Injections | 10 | 2020 | 45 | 0.710 |
Why?
| Infusion Pumps, Implantable | 1 | 2020 | 20 | 0.710 |
Why?
| Peptide Fragments | 4 | 2013 | 668 | 0.700 |
Why?
| Bleomycin | 3 | 2018 | 228 | 0.700 |
Why?
| Antihypertensive Agents | 2 | 2014 | 429 | 0.690 |
Why?
| Injections, Intraocular | 3 | 2017 | 10 | 0.680 |
Why?
| Endothelial Growth Factors | 4 | 2003 | 50 | 0.680 |
Why?
| Lymphokines | 4 | 2003 | 111 | 0.670 |
Why?
| Genetic Therapy | 5 | 2014 | 257 | 0.670 |
Why?
| Mitochondria | 3 | 2022 | 751 | 0.670 |
Why?
| Antibodies, Monoclonal, Humanized | 3 | 2013 | 664 | 0.660 |
Why?
| beta-Cyclodextrins | 3 | 2004 | 28 | 0.660 |
Why?
| Fluorescent Dyes | 5 | 2018 | 300 | 0.660 |
Why?
| Lung Injury | 2 | 2018 | 197 | 0.660 |
Why?
| Albumins | 2 | 2019 | 89 | 0.650 |
Why?
| Macular Degeneration | 5 | 2017 | 152 | 0.650 |
Why?
| Ephrin-A2 | 1 | 2018 | 3 | 0.640 |
Why?
| Microscopy, Confocal | 8 | 2020 | 305 | 0.640 |
Why?
| Lung | 5 | 2018 | 3546 | 0.640 |
Why?
| Retinal Diseases | 5 | 2014 | 76 | 0.640 |
Why?
| Cell Line | 17 | 2018 | 2639 | 0.630 |
Why?
| Chromatography, High Pressure Liquid | 12 | 2013 | 472 | 0.630 |
Why?
| Biological Transport | 9 | 2012 | 372 | 0.620 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2018 | 89 | 0.610 |
Why?
| Biological Availability | 9 | 2020 | 119 | 0.610 |
Why?
| Lipid Bilayers | 1 | 2019 | 99 | 0.610 |
Why?
| Fluorescein-5-isothiocyanate | 4 | 2016 | 37 | 0.600 |
Why?
| Microspheres | 4 | 2012 | 123 | 0.590 |
Why?
| Needles | 1 | 2017 | 49 | 0.580 |
Why?
| Fluorescein | 4 | 2018 | 25 | 0.580 |
Why?
| Area Under Curve | 7 | 2020 | 275 | 0.580 |
Why?
| Permeability | 9 | 2018 | 148 | 0.580 |
Why?
| Technology, Pharmaceutical | 2 | 2010 | 19 | 0.570 |
Why?
| Retinitis Pigmentosa | 2 | 2014 | 16 | 0.550 |
Why?
| Antineoplastic Agents | 6 | 2022 | 1895 | 0.550 |
Why?
| Rats, Inbred BN | 8 | 2011 | 52 | 0.550 |
Why?
| Cataract | 2 | 2011 | 185 | 0.540 |
Why?
| Cephalosporins | 3 | 2002 | 26 | 0.530 |
Why?
| Nanocapsules | 2 | 2013 | 8 | 0.520 |
Why?
| Endothelial Cells | 3 | 2018 | 681 | 0.510 |
Why?
| Electric Impedance | 4 | 2014 | 100 | 0.510 |
Why?
| Dinoprostone | 3 | 2009 | 184 | 0.500 |
Why?
| Disease Models, Animal | 15 | 2018 | 3542 | 0.500 |
Why?
| Humans | 64 | 2023 | 114709 | 0.500 |
Why?
| Epithelium, Corneal | 6 | 2018 | 37 | 0.490 |
Why?
| Pyridones | 2 | 2013 | 123 | 0.490 |
Why?
| Exfoliation Syndrome | 1 | 2014 | 10 | 0.480 |
Why?
| Leukostasis | 2 | 2011 | 3 | 0.480 |
Why?
| RNA, Messenger | 15 | 2012 | 2557 | 0.480 |
Why?
| Chemical Phenomena | 2 | 2011 | 80 | 0.450 |
Why?
| Light | 2 | 2013 | 336 | 0.450 |
Why?
| Male | 44 | 2020 | 55554 | 0.450 |
Why?
| Mice | 23 | 2023 | 14916 | 0.450 |
Why?
| Eye Proteins | 2 | 2012 | 71 | 0.440 |
Why?
| Transferrin | 3 | 2009 | 40 | 0.440 |
Why?
| Cell Proliferation | 8 | 2017 | 2196 | 0.440 |
Why?
| Posterior Eye Segment | 1 | 2013 | 2 | 0.440 |
Why?
| Chloroquine | 2 | 2012 | 52 | 0.440 |
Why?
| Serum Albumin, Bovine | 1 | 2013 | 62 | 0.430 |
Why?
| Tumor Necrosis Factor-alpha | 4 | 2018 | 1134 | 0.430 |
Why?
| Pyrimidines | 2 | 2017 | 378 | 0.430 |
Why?
| Glaucoma, Open-Angle | 1 | 2014 | 95 | 0.430 |
Why?
| Capsid Proteins | 1 | 2013 | 69 | 0.430 |
Why?
| Nanomedicine | 1 | 2013 | 28 | 0.430 |
Why?
| Poloxamer | 2 | 2002 | 11 | 0.420 |
Why?
| Pulmonary Fibrosis | 2 | 2013 | 322 | 0.420 |
Why?
| Salicylic Acid | 1 | 2012 | 8 | 0.420 |
Why?
| Adenoviridae | 1 | 2013 | 185 | 0.420 |
Why?
| Phenylalanine | 1 | 2012 | 57 | 0.420 |
Why?
| Fluocinolone Acetonide | 2 | 2011 | 16 | 0.420 |
Why?
| Geographic Atrophy | 1 | 2013 | 49 | 0.410 |
Why?
| Cyclooxygenase 2 | 4 | 2012 | 164 | 0.410 |
Why?
| Adrenergic beta-Antagonists | 4 | 2011 | 287 | 0.410 |
Why?
| Drug Implants | 3 | 2020 | 70 | 0.410 |
Why?
| Chlorides | 4 | 1998 | 127 | 0.410 |
Why?
| Adrenal Cortex Hormones | 3 | 2021 | 498 | 0.400 |
Why?
| Carbon Dioxide | 4 | 2013 | 218 | 0.400 |
Why?
| Corneal Neovascularization | 4 | 2015 | 12 | 0.400 |
Why?
| Bronchodilator Agents | 2 | 2005 | 240 | 0.400 |
Why?
| Drug Liberation | 3 | 2021 | 25 | 0.390 |
Why?
| Injections | 8 | 2011 | 159 | 0.390 |
Why?
| Probenecid | 2 | 2009 | 7 | 0.390 |
Why?
| Tyrosine | 1 | 2012 | 215 | 0.390 |
Why?
| Antioxidants | 2 | 2014 | 530 | 0.390 |
Why?
| STAT1 Transcription Factor | 1 | 2011 | 65 | 0.380 |
Why?
| Thiazines | 1 | 2011 | 9 | 0.380 |
Why?
| Oxidative Stress | 5 | 2021 | 1084 | 0.380 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 2 | 2009 | 103 | 0.380 |
Why?
| Bevacizumab | 4 | 2017 | 115 | 0.380 |
Why?
| Macular Edema | 1 | 2011 | 34 | 0.370 |
Why?
| Mitochondrial Diseases | 1 | 2011 | 77 | 0.370 |
Why?
| Absorbable Implants | 2 | 2020 | 34 | 0.370 |
Why?
| Oligonucleotides, Antisense | 3 | 2009 | 100 | 0.370 |
Why?
| Polyglactin 910 | 2 | 2012 | 6 | 0.360 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 9 | 2012 | 928 | 0.360 |
Why?
| Thiophenes | 1 | 2011 | 108 | 0.360 |
Why?
| Poly G | 1 | 2010 | 1 | 0.360 |
Why?
| Suspensions | 3 | 2020 | 30 | 0.360 |
Why?
| Diclofenac | 2 | 2009 | 14 | 0.350 |
Why?
| Trabecular Meshwork | 1 | 2011 | 77 | 0.350 |
Why?
| Fluoroquinolones | 1 | 2010 | 41 | 0.350 |
Why?
| Micelles | 1 | 2010 | 34 | 0.350 |
Why?
| Solvents | 5 | 2013 | 105 | 0.350 |
Why?
| Solubility | 5 | 2011 | 224 | 0.350 |
Why?
| Retinal Neovascularization | 4 | 2015 | 20 | 0.350 |
Why?
| Vascular Diseases | 1 | 2012 | 230 | 0.340 |
Why?
| Adjuvants, Pharmaceutic | 1 | 2009 | 10 | 0.340 |
Why?
| Drug Stability | 6 | 2011 | 151 | 0.340 |
Why?
| Gene Expression | 5 | 2018 | 1420 | 0.330 |
Why?
| Chorioallantoic Membrane | 1 | 2009 | 3 | 0.330 |
Why?
| Porosity | 4 | 2013 | 89 | 0.330 |
Why?
| Lung Neoplasms | 5 | 2017 | 2199 | 0.330 |
Why?
| Cell Survival | 6 | 2013 | 1021 | 0.330 |
Why?
| Taxoids | 1 | 2009 | 94 | 0.320 |
Why?
| Quantitative Structure-Activity Relationship | 1 | 2008 | 13 | 0.320 |
Why?
| Plasmids | 5 | 2017 | 345 | 0.320 |
Why?
| Receptor, EphA2 | 2 | 2018 | 19 | 0.310 |
Why?
| Dose-Response Relationship, Drug | 8 | 2017 | 1846 | 0.310 |
Why?
| Models, Animal | 2 | 2020 | 345 | 0.310 |
Why?
| Spectroscopy, Fourier Transform Infrared | 4 | 2010 | 76 | 0.310 |
Why?
| Endothelium, Corneal | 2 | 2021 | 15 | 0.310 |
Why?
| DNA-Binding Proteins | 3 | 2023 | 1314 | 0.310 |
Why?
| Pharmacokinetics | 4 | 2012 | 25 | 0.310 |
Why?
| Injections, Intravenous | 5 | 2017 | 201 | 0.310 |
Why?
| Eye Color | 1 | 2008 | 3 | 0.300 |
Why?
| Protein-Tyrosine Kinases | 1 | 2011 | 398 | 0.300 |
Why?
| Green Fluorescent Proteins | 1 | 2009 | 373 | 0.300 |
Why?
| Bruch Membrane | 2 | 2011 | 6 | 0.300 |
Why?
| Vascular Endothelial Growth Factors | 5 | 2011 | 61 | 0.300 |
Why?
| Retinal Pigments | 1 | 2007 | 5 | 0.300 |
Why?
| Drug Administration Routes | 4 | 2009 | 40 | 0.300 |
Why?
| Photosensitizing Agents | 1 | 2008 | 26 | 0.300 |
Why?
| Receptors, Glucocorticoid | 1 | 2009 | 130 | 0.300 |
Why?
| Medical Oncology | 1 | 2009 | 229 | 0.290 |
Why?
| Lasers | 3 | 2021 | 121 | 0.290 |
Why?
| Anti-Infective Agents | 1 | 2010 | 225 | 0.290 |
Why?
| Anthraquinones | 1 | 2007 | 9 | 0.290 |
Why?
| Chemistry, Pharmaceutical | 4 | 2012 | 98 | 0.290 |
Why?
| Imidazolidines | 1 | 2007 | 8 | 0.290 |
Why?
| Indomethacin | 2 | 2004 | 70 | 0.290 |
Why?
| Fluorophotometry | 2 | 2020 | 3 | 0.290 |
Why?
| Dogs | 3 | 2012 | 334 | 0.280 |
Why?
| DNA | 2 | 2013 | 1351 | 0.280 |
Why?
| Macula Lutea | 1 | 2007 | 15 | 0.280 |
Why?
| ELAV-Like Protein 1 | 2 | 2017 | 15 | 0.280 |
Why?
| Microscopy, Electron, Scanning | 5 | 2005 | 192 | 0.280 |
Why?
| Rhodamines | 1 | 2006 | 17 | 0.280 |
Why?
| Mannitol | 1 | 2006 | 32 | 0.270 |
Why?
| Reproducibility of Results | 3 | 2022 | 2762 | 0.270 |
Why?
| Serum Albumin | 1 | 2007 | 134 | 0.270 |
Why?
| Blotting, Western | 7 | 2013 | 1151 | 0.260 |
Why?
| Protein Kinase Inhibitors | 1 | 2011 | 795 | 0.260 |
Why?
| Hydrogen-Ion Concentration | 5 | 2015 | 511 | 0.250 |
Why?
| Superoxide Dismutase | 1 | 2007 | 305 | 0.250 |
Why?
| Enzyme-Linked Immunosorbent Assay | 5 | 2013 | 797 | 0.250 |
Why?
| Aldehydes | 2 | 2005 | 142 | 0.250 |
Why?
| Time Factors | 12 | 2015 | 6122 | 0.240 |
Why?
| Cell Line, Tumor | 7 | 2022 | 2725 | 0.240 |
Why?
| Triamcinolone Acetonide | 3 | 2021 | 27 | 0.240 |
Why?
| Swine | 5 | 2021 | 700 | 0.240 |
Why?
| Magnetic Resonance Spectroscopy | 3 | 2013 | 473 | 0.240 |
Why?
| Glutathione | 2 | 2005 | 300 | 0.240 |
Why?
| Buserelin | 1 | 2004 | 1 | 0.240 |
Why?
| DNA Helicases | 2 | 2023 | 134 | 0.230 |
Why?
| Oligopeptides | 3 | 2011 | 234 | 0.230 |
Why?
| Orphan Nuclear Receptors | 3 | 2014 | 14 | 0.230 |
Why?
| Cell Membrane Permeability | 4 | 2018 | 83 | 0.230 |
Why?
| In Vitro Techniques | 6 | 2012 | 1013 | 0.220 |
Why?
| Lysosomes | 2 | 2015 | 123 | 0.220 |
Why?
| Mice, Inbred BALB C | 6 | 2014 | 1151 | 0.220 |
Why?
| Arthritis, Rheumatoid | 1 | 2011 | 1001 | 0.220 |
Why?
| Half-Life | 3 | 2009 | 141 | 0.220 |
Why?
| Cell Cycle | 3 | 2013 | 543 | 0.210 |
Why?
| Circular Dichroism | 2 | 2013 | 135 | 0.210 |
Why?
| Respiratory System | 1 | 2004 | 137 | 0.210 |
Why?
| Octanols | 1 | 2022 | 1 | 0.210 |
Why?
| Polyesters | 3 | 2013 | 64 | 0.210 |
Why?
| Liposomes | 3 | 2011 | 146 | 0.210 |
Why?
| Cysteine Proteinase Inhibitors | 1 | 2002 | 45 | 0.210 |
Why?
| Linear Models | 3 | 2009 | 770 | 0.200 |
Why?
| Protein Structure, Secondary | 2 | 2013 | 325 | 0.200 |
Why?
| Temperature | 5 | 2004 | 575 | 0.200 |
Why?
| Multidrug Resistance-Associated Proteins | 1 | 2002 | 35 | 0.200 |
Why?
| Prostatic Neoplasms | 1 | 2009 | 925 | 0.200 |
Why?
| Protein Aggregates | 1 | 2022 | 65 | 0.200 |
Why?
| alpha-Cyclodextrins | 1 | 2001 | 1 | 0.200 |
Why?
| Transfection | 3 | 2015 | 870 | 0.200 |
Why?
| Biocompatible Materials | 2 | 2020 | 369 | 0.200 |
Why?
| Cyclodextrins | 1 | 2001 | 8 | 0.200 |
Why?
| Chymotrypsin | 1 | 2001 | 16 | 0.200 |
Why?
| Thiazolidinediones | 2 | 2013 | 142 | 0.200 |
Why?
| Drug Evaluation, Preclinical | 4 | 2017 | 165 | 0.200 |
Why?
| Rhodopsin | 2 | 2011 | 9 | 0.190 |
Why?
| Models, Molecular | 2 | 2019 | 1378 | 0.190 |
Why?
| Electroretinography | 4 | 2018 | 40 | 0.190 |
Why?
| Brain | 2 | 2011 | 2369 | 0.190 |
Why?
| Cystinosis | 1 | 2021 | 1 | 0.190 |
Why?
| Contact Lenses | 1 | 2021 | 7 | 0.190 |
Why?
| Cystine | 1 | 2021 | 14 | 0.190 |
Why?
| Fluorescein Angiography | 4 | 2017 | 102 | 0.190 |
Why?
| Zinc Compounds | 2 | 1998 | 7 | 0.190 |
Why?
| Oncogenes | 2 | 2022 | 107 | 0.190 |
Why?
| Edetic Acid | 2 | 1998 | 47 | 0.190 |
Why?
| Carboplatin | 2 | 2013 | 135 | 0.190 |
Why?
| Respiratory Mucosa | 1 | 2003 | 251 | 0.180 |
Why?
| Uveitis | 2 | 2014 | 115 | 0.180 |
Why?
| Eye Burns | 2 | 2013 | 11 | 0.180 |
Why?
| Proteins | 2 | 2001 | 912 | 0.180 |
Why?
| Molecular Weight | 2 | 2013 | 331 | 0.180 |
Why?
| Hypromellose Derivatives | 1 | 2020 | 1 | 0.180 |
Why?
| Therapeutic Equivalency | 1 | 2020 | 18 | 0.180 |
Why?
| Mice, Nude | 3 | 2017 | 635 | 0.180 |
Why?
| Collagen | 2 | 2013 | 415 | 0.180 |
Why?
| Cytoskeleton | 1 | 2021 | 177 | 0.180 |
Why?
| Symporters | 1 | 2020 | 52 | 0.180 |
Why?
| Pyramidal Cells | 1 | 2020 | 50 | 0.180 |
Why?
| Corneal Stroma | 2 | 2018 | 16 | 0.180 |
Why?
| Prodrugs | 1 | 2000 | 42 | 0.180 |
Why?
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2013 | 66 | 0.170 |
Why?
| Cholic Acids | 2 | 2011 | 17 | 0.170 |
Why?
| Administration, Oral | 3 | 2012 | 731 | 0.170 |
Why?
| Ophthalmology | 1 | 2021 | 77 | 0.170 |
Why?
| Benzo(a)pyrene | 2 | 2013 | 7 | 0.170 |
Why?
| 2-Hydroxypropyl-beta-cyclodextrin | 3 | 2004 | 6 | 0.170 |
Why?
| Body Weight | 3 | 2011 | 869 | 0.170 |
Why?
| Thermodynamics | 1 | 2001 | 383 | 0.170 |
Why?
| Gene Expression Regulation | 6 | 2018 | 2321 | 0.170 |
Why?
| Prednisolone | 2 | 2011 | 75 | 0.170 |
Why?
| Mice, Inbred C57BL | 8 | 2018 | 4710 | 0.160 |
Why?
| Drug Monitoring | 1 | 2020 | 184 | 0.160 |
Why?
| Synovial Fluid | 1 | 1999 | 57 | 0.160 |
Why?
| Adsorption | 1 | 2019 | 119 | 0.160 |
Why?
| Chitosan | 2 | 2016 | 28 | 0.160 |
Why?
| Molecular Targeted Therapy | 2 | 2011 | 347 | 0.160 |
Why?
| Models, Biological | 3 | 2013 | 1630 | 0.160 |
Why?
| Glioma | 1 | 2022 | 294 | 0.160 |
Why?
| Drug Administration Schedule | 2 | 2011 | 718 | 0.150 |
Why?
| Chemistry, Physical | 2 | 2009 | 37 | 0.150 |
Why?
| Gene Silencing | 3 | 2017 | 172 | 0.150 |
Why?
| Cells, Cultured | 6 | 2018 | 3890 | 0.150 |
Why?
| Surface Properties | 1 | 2019 | 387 | 0.150 |
Why?
| Neovascularization, Pathologic | 2 | 2013 | 283 | 0.150 |
Why?
| Endoplasmic Reticulum | 2 | 2018 | 234 | 0.150 |
Why?
| Endoplasmic Reticulum Stress | 1 | 2018 | 91 | 0.150 |
Why?
| Regional Blood Flow | 2 | 2011 | 424 | 0.150 |
Why?
| Drug Interactions | 3 | 2013 | 340 | 0.150 |
Why?
| Molecular Structure | 2 | 2009 | 438 | 0.150 |
Why?
| Glycoproteins | 1 | 1999 | 304 | 0.150 |
Why?
| Drug Combinations | 2 | 2011 | 286 | 0.150 |
Why?
| Action Potentials | 1 | 2020 | 406 | 0.150 |
Why?
| Excipients | 2 | 2001 | 49 | 0.140 |
Why?
| Turbinates | 2 | 2008 | 12 | 0.140 |
Why?
| Bronchoalveolar Lavage Fluid | 2 | 2013 | 589 | 0.140 |
Why?
| Dextran Sulfate | 1 | 2016 | 70 | 0.140 |
Why?
| RNAi Therapeutics | 1 | 2016 | 3 | 0.140 |
Why?
| Mifepristone | 2 | 2009 | 60 | 0.140 |
Why?
| Female | 16 | 2020 | 59483 | 0.130 |
Why?
| Surgeons | 1 | 2020 | 237 | 0.130 |
Why?
| Folate Receptor 1 | 1 | 2016 | 13 | 0.130 |
Why?
| 2,4-Dinitrophenol | 3 | 2004 | 8 | 0.130 |
Why?
| Immunoconjugates | 1 | 2017 | 87 | 0.130 |
Why?
| Signal Transduction | 2 | 2013 | 4521 | 0.130 |
Why?
| Hippocampus | 1 | 2020 | 695 | 0.130 |
Why?
| Aryl Hydrocarbon Hydroxylases | 2 | 2013 | 41 | 0.130 |
Why?
| Central Nervous System | 1 | 1998 | 237 | 0.130 |
Why?
| Indazoles | 2 | 2017 | 58 | 0.130 |
Why?
| Transient Receptor Potential Channels | 1 | 2015 | 3 | 0.130 |
Why?
| Precision Medicine | 1 | 2019 | 338 | 0.130 |
Why?
| Vacuolar Proton-Translocating ATPases | 1 | 2015 | 12 | 0.130 |
Why?
| Presenilin-1 | 1 | 2015 | 27 | 0.130 |
Why?
| Wnt3A Protein | 1 | 2015 | 7 | 0.120 |
Why?
| Cyclic AMP | 1 | 1996 | 225 | 0.120 |
Why?
| Receptors, LDL | 1 | 2015 | 38 | 0.120 |
Why?
| Mucous Membrane | 3 | 1996 | 108 | 0.120 |
Why?
| Blood Glucose | 3 | 2011 | 1821 | 0.120 |
Why?
| Sodium | 2 | 1996 | 182 | 0.120 |
Why?
| Absorption | 2 | 2004 | 52 | 0.120 |
Why?
| Administration, Intranasal | 2 | 2009 | 75 | 0.120 |
Why?
| Retinal Vessels | 1 | 2015 | 50 | 0.120 |
Why?
| Vaccine Potency | 1 | 2014 | 6 | 0.120 |
Why?
| Microbial Sensitivity Tests | 2 | 2010 | 301 | 0.120 |
Why?
| Phagocytosis | 2 | 2013 | 350 | 0.120 |
Why?
| Aluminum Hydroxide | 1 | 2014 | 12 | 0.120 |
Why?
| Injections, Intraperitoneal | 2 | 2004 | 100 | 0.120 |
Why?
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 316 | 0.120 |
Why?
| Nuclear Receptor Subfamily 1, Group D, Member 1 | 1 | 2014 | 3 | 0.120 |
Why?
| Plasminogen | 2 | 2011 | 33 | 0.110 |
Why?
| Fibrosis | 2 | 2013 | 453 | 0.110 |
Why?
| Eye Diseases, Hereditary | 1 | 2014 | 11 | 0.110 |
Why?
| Hepatitis B Vaccines | 1 | 2014 | 46 | 0.110 |
Why?
| Freezing | 1 | 2014 | 85 | 0.110 |
Why?
| Prostaglandin-Endoperoxide Synthases | 2 | 2004 | 58 | 0.110 |
Why?
| Acetophenones | 1 | 2013 | 14 | 0.110 |
Why?
| Cholesterol | 2 | 2016 | 368 | 0.110 |
Why?
| Treatment Outcome | 6 | 2014 | 9089 | 0.110 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2014 | 119 | 0.110 |
Why?
| Tight Junctions | 1 | 2014 | 68 | 0.110 |
Why?
| Withanolides | 1 | 2013 | 1 | 0.110 |
Why?
| Calorimetry, Differential Scanning | 2 | 2004 | 34 | 0.110 |
Why?
| Retinal Rod Photoreceptor Cells | 1 | 2013 | 11 | 0.110 |
Why?
| Micro-Electrical-Mechanical Systems | 1 | 2013 | 5 | 0.110 |
Why?
| Wnt Signaling Pathway | 1 | 2015 | 147 | 0.110 |
Why?
| Chromatography, Gel | 1 | 2013 | 123 | 0.110 |
Why?
| alpha-Crystallin A Chain | 1 | 2013 | 8 | 0.110 |
Why?
| Cell Shape | 1 | 2013 | 54 | 0.110 |
Why?
| Capsid | 1 | 2013 | 75 | 0.110 |
Why?
| L-Lactate Dehydrogenase | 1 | 2013 | 107 | 0.110 |
Why?
| Vimentin | 1 | 2013 | 58 | 0.110 |
Why?
| Gemfibrozil | 1 | 2013 | 10 | 0.110 |
Why?
| Trachea | 2 | 2005 | 223 | 0.110 |
Why?
| Scattering, Radiation | 1 | 2013 | 92 | 0.110 |
Why?
| Monophenol Monooxygenase | 1 | 2012 | 9 | 0.110 |
Why?
| Corneal Injuries | 1 | 2013 | 34 | 0.110 |
Why?
| Sensitivity and Specificity | 2 | 2008 | 1690 | 0.110 |
Why?
| Madin Darby Canine Kidney Cells | 1 | 2012 | 14 | 0.110 |
Why?
| Receptors, Transferrin | 2 | 2017 | 22 | 0.110 |
Why?
| Adjuvants, Immunologic | 1 | 2014 | 206 | 0.110 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2013 | 138 | 0.100 |
Why?
| Levodopa | 1 | 2012 | 23 | 0.100 |
Why?
| Pressure | 1 | 2013 | 218 | 0.100 |
Why?
| Vision Disorders | 1 | 2014 | 130 | 0.100 |
Why?
| Bronchoalveolar Lavage | 1 | 2012 | 84 | 0.100 |
Why?
| Timolol | 2 | 2011 | 14 | 0.100 |
Why?
| Protein Stability | 1 | 2013 | 157 | 0.100 |
Why?
| Inflammation | 2 | 2020 | 2481 | 0.100 |
Why?
| Gels | 2 | 2002 | 72 | 0.100 |
Why?
| Ouabain | 3 | 1998 | 15 | 0.100 |
Why?
| Cell Count | 1 | 2013 | 305 | 0.100 |
Why?
| Corneal Diseases | 1 | 2012 | 34 | 0.100 |
Why?
| Doxycycline | 1 | 2012 | 55 | 0.100 |
Why?
| Colorimetry | 1 | 2012 | 14 | 0.100 |
Why?
| Lymphangiogenesis | 1 | 2012 | 24 | 0.100 |
Why?
| Pigmentation | 1 | 2012 | 55 | 0.100 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 195 | 0.100 |
Why?
| Hypolipidemic Agents | 1 | 2013 | 87 | 0.100 |
Why?
| MicroRNAs | 1 | 2018 | 601 | 0.100 |
Why?
| Aqueous Humor | 2 | 2014 | 31 | 0.100 |
Why?
| Macaca fascicularis | 1 | 2012 | 51 | 0.100 |
Why?
| Paclitaxel | 1 | 2013 | 190 | 0.100 |
Why?
| Xenograft Model Antitumor Assays | 2 | 2017 | 706 | 0.100 |
Why?
| Computer Simulation | 2 | 2018 | 878 | 0.100 |
Why?
| Cloning, Molecular | 1 | 2013 | 524 | 0.100 |
Why?
| Membrane Transport Proteins | 1 | 2013 | 138 | 0.100 |
Why?
| Endothelium, Vascular | 1 | 2018 | 843 | 0.100 |
Why?
| Apoptosis | 4 | 2013 | 2369 | 0.100 |
Why?
| Swine, Miniature | 1 | 2012 | 71 | 0.100 |
Why?
| Microscopy, Phase-Contrast | 1 | 2011 | 18 | 0.100 |
Why?
| Anti-Bacterial Agents | 2 | 2012 | 1477 | 0.100 |
Why?
| Drug Discovery | 1 | 2012 | 124 | 0.100 |
Why?
| Carbon | 1 | 2012 | 157 | 0.100 |
Why?
| Carbonic Anhydrase Inhibitors | 1 | 2011 | 17 | 0.100 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2011 | 55 | 0.100 |
Why?
| Propranolol | 1 | 2011 | 49 | 0.100 |
Why?
| Amino Acids | 1 | 1995 | 448 | 0.090 |
Why?
| HEK293 Cells | 1 | 2013 | 593 | 0.090 |
Why?
| Wound Healing | 1 | 2013 | 258 | 0.090 |
Why?
| Quinoxalines | 1 | 2011 | 60 | 0.090 |
Why?
| Rats, Wistar | 1 | 2012 | 368 | 0.090 |
Why?
| Optic Nerve | 1 | 2011 | 65 | 0.090 |
Why?
| Cross-Sectional Studies | 1 | 2021 | 4406 | 0.090 |
Why?
| Curcumin | 1 | 2011 | 28 | 0.090 |
Why?
| Diffusion Chambers, Culture | 2 | 2010 | 6 | 0.090 |
Why?
| Biological Transport, Active | 4 | 2010 | 71 | 0.090 |
Why?
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2011 | 73 | 0.090 |
Why?
| Materials Testing | 1 | 2012 | 337 | 0.090 |
Why?
| Chemical Warfare Agents | 1 | 2012 | 120 | 0.090 |
Why?
| Ion Transport | 3 | 1996 | 55 | 0.090 |
Why?
| Gold | 2 | 2022 | 106 | 0.090 |
Why?
| Silymarin | 1 | 2012 | 194 | 0.090 |
Why?
| Lipogenesis | 1 | 2011 | 57 | 0.090 |
Why?
| Pregnadienediols | 1 | 2010 | 2 | 0.090 |
Why?
| Calorimetry | 1 | 2010 | 60 | 0.090 |
Why?
| Neoplasms | 1 | 2023 | 2105 | 0.090 |
Why?
| Leukocytes | 1 | 2011 | 277 | 0.090 |
Why?
| Chromatography, Supercritical Fluid | 1 | 2009 | 3 | 0.090 |
Why?
| Stress, Physiological | 1 | 2013 | 379 | 0.090 |
Why?
| Graft Survival | 1 | 2012 | 452 | 0.080 |
Why?
| Emulsions | 1 | 2009 | 42 | 0.080 |
Why?
| Interleukin-10 | 1 | 2011 | 296 | 0.080 |
Why?
| Polymorphism, Genetic | 1 | 2013 | 612 | 0.080 |
Why?
| Calcium | 1 | 2015 | 1103 | 0.080 |
Why?
| Flow Cytometry | 2 | 2012 | 1086 | 0.080 |
Why?
| Dosage Forms | 1 | 2009 | 10 | 0.080 |
Why?
| Blood Proteins | 1 | 2011 | 232 | 0.080 |
Why?
| Aging | 1 | 2019 | 1620 | 0.080 |
Why?
| Neoplasm Transplantation | 1 | 2009 | 232 | 0.080 |
Why?
| Retinal Neoplasms | 1 | 2009 | 21 | 0.080 |
Why?
| Genetic Vectors | 2 | 2007 | 291 | 0.080 |
Why?
| Retinoblastoma | 1 | 2009 | 26 | 0.080 |
Why?
| Anticholesteremic Agents | 1 | 2011 | 128 | 0.080 |
Why?
| Chick Embryo | 1 | 2009 | 122 | 0.080 |
Why?
| Vinblastine | 1 | 2009 | 62 | 0.080 |
Why?
| Cell Membrane | 1 | 2012 | 679 | 0.080 |
Why?
| Drug Synergism | 1 | 2009 | 316 | 0.080 |
Why?
| Least-Squares Analysis | 1 | 2008 | 70 | 0.080 |
Why?
| Calibration | 1 | 2008 | 125 | 0.080 |
Why?
| Tumor Burden | 1 | 2009 | 261 | 0.080 |
Why?
| Hydrocortisone | 1 | 2010 | 269 | 0.080 |
Why?
| Validation Studies as Topic | 1 | 2008 | 23 | 0.080 |
Why?
| Mice, Transgenic | 4 | 2018 | 1951 | 0.080 |
Why?
| Lipid Metabolism | 1 | 2011 | 446 | 0.070 |
Why?
| Thionucleotides | 1 | 2007 | 34 | 0.070 |
Why?
| Photochemotherapy | 1 | 2008 | 29 | 0.070 |
Why?
| Tosylphenylalanyl Chloromethyl Ketone | 2 | 1998 | 3 | 0.070 |
Why?
| Ethylmaleimide | 2 | 1998 | 18 | 0.070 |
Why?
| Cell Movement | 3 | 2017 | 867 | 0.070 |
Why?
| Methicillin-Resistant Staphylococcus aureus | 1 | 2010 | 191 | 0.070 |
Why?
| Neovascularization, Physiologic | 1 | 2009 | 173 | 0.070 |
Why?
| Clinical Trials, Phase III as Topic | 1 | 2007 | 82 | 0.070 |
Why?
| Doxorubicin | 1 | 2009 | 286 | 0.070 |
Why?
| Caveolae | 1 | 2007 | 15 | 0.070 |
Why?
| Macrophages | 2 | 2011 | 1261 | 0.070 |
Why?
| Models, Anatomic | 1 | 2008 | 87 | 0.070 |
Why?
| Clathrin | 1 | 2007 | 27 | 0.070 |
Why?
| Pharmaceutical Vehicles | 1 | 2007 | 11 | 0.070 |
Why?
| Species Specificity | 1 | 2008 | 545 | 0.070 |
Why?
| Galactose | 1 | 2007 | 20 | 0.070 |
Why?
| Software | 1 | 2011 | 536 | 0.070 |
Why?
| Mydriasis | 1 | 2007 | 8 | 0.070 |
Why?
| Vacuoles | 1 | 2007 | 33 | 0.070 |
Why?
| Cells | 1 | 2007 | 22 | 0.070 |
Why?
| Glycopeptides | 2 | 1998 | 43 | 0.070 |
Why?
| Burns, Chemical | 1 | 2007 | 25 | 0.070 |
Why?
| Pulmonary Alveoli | 1 | 2009 | 372 | 0.070 |
Why?
| Receptors, Cytoplasmic and Nuclear | 1 | 2008 | 193 | 0.070 |
Why?
| Macaca mulatta | 1 | 2007 | 131 | 0.070 |
Why?
| Aptamers, Nucleotide | 1 | 2007 | 73 | 0.070 |
Why?
| Alzheimer Disease | 1 | 2011 | 436 | 0.070 |
Why?
| Diffusion | 2 | 2009 | 118 | 0.070 |
Why?
| Ketorolac Tromethamine | 1 | 2006 | 3 | 0.070 |
Why?
| Cell Hypoxia | 1 | 2007 | 220 | 0.070 |
Why?
| Mass Spectrometry | 1 | 2009 | 633 | 0.070 |
Why?
| Electrophysiology | 3 | 1996 | 201 | 0.060 |
Why?
| Hydrogels | 1 | 2012 | 573 | 0.060 |
Why?
| Kidney | 1 | 2012 | 1184 | 0.060 |
Why?
| Thiobarbituric Acid Reactive Substances | 1 | 2005 | 20 | 0.060 |
Why?
| Lymph Nodes | 1 | 2008 | 423 | 0.060 |
Why?
| Glutathione Disulfide | 1 | 2005 | 26 | 0.060 |
Why?
| Hypoglycemic Agents | 1 | 2013 | 1008 | 0.060 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 1361 | 0.060 |
Why?
| Dextrans | 2 | 2016 | 74 | 0.060 |
Why?
| Injections, Intramuscular | 1 | 2005 | 117 | 0.060 |
Why?
| Atherosclerosis | 1 | 2008 | 342 | 0.060 |
Why?
| Carcinogens | 1 | 2005 | 105 | 0.060 |
Why?
| Cyclooxygenase 1 | 1 | 2004 | 20 | 0.060 |
Why?
| Antibodies, Monoclonal | 1 | 2011 | 1270 | 0.060 |
Why?
| Oligoribonucleotides, Antisense | 1 | 2004 | 3 | 0.060 |
Why?
| Pharmaceutical Solutions | 1 | 2004 | 14 | 0.060 |
Why?
| X-Ray Diffraction | 1 | 2004 | 84 | 0.060 |
Why?
| Powders | 1 | 2004 | 38 | 0.060 |
Why?
| Cell Nucleus | 1 | 2007 | 554 | 0.060 |
Why?
| Immunohistochemistry | 3 | 2013 | 1635 | 0.060 |
Why?
| Diabetes Mellitus | 1 | 2011 | 904 | 0.060 |
Why?
| Predictive Value of Tests | 1 | 2008 | 1795 | 0.060 |
Why?
| Cell Culture Techniques | 1 | 2006 | 343 | 0.060 |
Why?
| Fluorescent Antibody Technique | 1 | 2004 | 396 | 0.050 |
Why?
| Cytochrome P-450 CYP2C8 | 2 | 2013 | 15 | 0.050 |
Why?
| Hormone Antagonists | 1 | 2003 | 33 | 0.050 |
Why?
| Cytosol | 1 | 2003 | 208 | 0.050 |
Why?
| Administration, Inhalation | 1 | 2004 | 642 | 0.050 |
Why?
| Middle Aged | 5 | 2018 | 26747 | 0.050 |
Why?
| Theranostic Nanomedicine | 1 | 2022 | 8 | 0.050 |
Why?
| Indocyanine Green | 1 | 2022 | 12 | 0.050 |
Why?
| Flow Injection Analysis | 1 | 2002 | 5 | 0.050 |
Why?
| Phototherapy | 1 | 2022 | 24 | 0.050 |
Why?
| Lipid Peroxidation | 1 | 2002 | 139 | 0.050 |
Why?
| Dialysis | 1 | 2002 | 17 | 0.050 |
Why?
| Verapamil | 1 | 2002 | 32 | 0.050 |
Why?
| Fuchs' Endothelial Dystrophy | 1 | 2021 | 1 | 0.050 |
Why?
| Antiviral Agents | 1 | 2007 | 646 | 0.050 |
Why?
| Chemical Precipitation | 1 | 2002 | 37 | 0.050 |
Why?
| Amino Acids, Aromatic | 1 | 2001 | 7 | 0.050 |
Why?
| Chronic Disease | 1 | 2008 | 1590 | 0.050 |
Why?
| Isoenzymes | 1 | 2003 | 285 | 0.050 |
Why?
| Capsules | 1 | 2002 | 36 | 0.050 |
Why?
| Vincristine | 1 | 2002 | 100 | 0.050 |
Why?
| Solutions | 1 | 2002 | 146 | 0.050 |
Why?
| Tetrazolium Salts | 1 | 2001 | 18 | 0.050 |
Why?
| Antimetabolites | 1 | 2001 | 21 | 0.050 |
Why?
| Indicators and Reagents | 1 | 2001 | 99 | 0.050 |
Why?
| Spectrometry, Fluorescence | 1 | 2001 | 157 | 0.050 |
Why?
| Ascorbic Acid | 1 | 2021 | 110 | 0.050 |
Why?
| Drug Design | 1 | 2022 | 151 | 0.050 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2021 | 262 | 0.050 |
Why?
| Thiazoles | 1 | 2001 | 110 | 0.050 |
Why?
| Carcinogenesis | 1 | 2022 | 180 | 0.040 |
Why?
| Cold Temperature | 1 | 2001 | 128 | 0.040 |
Why?
| Metal Nanoparticles | 1 | 2021 | 75 | 0.040 |
Why?
| Hydrolysis | 1 | 2000 | 175 | 0.040 |
Why?
| Liver X Receptors | 2 | 2011 | 30 | 0.040 |
Why?
| Microtubules | 1 | 2021 | 237 | 0.040 |
Why?
| Stereoisomerism | 1 | 1999 | 91 | 0.040 |
Why?
| Mannheimia haemolytica | 1 | 1999 | 1 | 0.040 |
Why?
| Protein Conformation | 1 | 2001 | 811 | 0.040 |
Why?
| Receptor, TIE-2 | 1 | 2018 | 12 | 0.040 |
Why?
| Instillation, Drug | 1 | 2018 | 9 | 0.040 |
Why?
| Streptozocin | 1 | 2018 | 17 | 0.040 |
Why?
| Fluorometry | 1 | 2018 | 19 | 0.040 |
Why?
| Tears | 1 | 2018 | 14 | 0.040 |
Why?
| Protein Binding | 1 | 2004 | 1896 | 0.040 |
Why?
| Membrane Proteins | 1 | 2004 | 1022 | 0.040 |
Why?
| Electroencephalography | 1 | 2020 | 362 | 0.040 |
Why?
| Dithiothreitol | 1 | 1998 | 17 | 0.040 |
Why?
| Random Allocation | 1 | 1999 | 335 | 0.040 |
Why?
| Monte Carlo Method | 1 | 2018 | 137 | 0.040 |
Why?
| Antibiotics, Antineoplastic | 1 | 2018 | 109 | 0.040 |
Why?
| Seizures | 1 | 2020 | 339 | 0.040 |
Why?
| Olfactory Pathways | 1 | 1998 | 56 | 0.040 |
Why?
| Fatty Liver | 2 | 2011 | 213 | 0.040 |
Why?
| Cerebrospinal Fluid | 1 | 1998 | 90 | 0.040 |
Why?
| G1 Phase | 1 | 2017 | 68 | 0.040 |
Why?
| Static Electricity | 1 | 2017 | 114 | 0.040 |
Why?
| Cell Cycle Checkpoints | 1 | 2017 | 85 | 0.030 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2017 | 155 | 0.030 |
Why?
| Visual Acuity | 1 | 2018 | 274 | 0.030 |
Why?
| Protease Inhibitors | 1 | 1997 | 97 | 0.030 |
Why?
| Gene Knockdown Techniques | 1 | 2017 | 299 | 0.030 |
Why?
| Staining and Labeling | 1 | 2016 | 134 | 0.030 |
Why?
| Monosaccharide Transport Proteins | 1 | 1996 | 45 | 0.030 |
Why?
| Terbutaline | 1 | 1996 | 8 | 0.030 |
Why?
| 8-Bromo Cyclic Adenosine Monophosphate | 1 | 1996 | 17 | 0.030 |
Why?
| Primary Cell Culture | 1 | 2016 | 149 | 0.030 |
Why?
| Colforsin | 1 | 1996 | 44 | 0.030 |
Why?
| Complement C3 | 1 | 2017 | 189 | 0.030 |
Why?
| Neoplasm Invasiveness | 1 | 2017 | 445 | 0.030 |
Why?
| Theophylline | 1 | 1996 | 60 | 0.030 |
Why?
| Endocytosis | 1 | 2016 | 149 | 0.030 |
Why?
| Phosphodiesterase Inhibitors | 1 | 1996 | 82 | 0.030 |
Why?
| Analysis of Variance | 1 | 2018 | 1226 | 0.030 |
Why?
| Calcium Channel Blockers | 1 | 1996 | 115 | 0.030 |
Why?
| Low Density Lipoprotein Receptor-Related Protein-6 | 1 | 2015 | 6 | 0.030 |
Why?
| Folic Acid | 1 | 2016 | 161 | 0.030 |
Why?
| Adrenergic beta-Agonists | 1 | 1996 | 125 | 0.030 |
Why?
| Proteolysis | 1 | 2015 | 143 | 0.030 |
Why?
| Hemoglobins | 1 | 2017 | 314 | 0.030 |
Why?
| Epinephrine | 1 | 1996 | 164 | 0.030 |
Why?
| Hepatitis B Surface Antigens | 1 | 2014 | 18 | 0.030 |
Why?
| Zonula Occludens-1 Protein | 1 | 2014 | 13 | 0.030 |
Why?
| Matrix Metalloproteinase Inhibitors | 1 | 2014 | 13 | 0.030 |
Why?
| Cycloheximide | 1 | 2014 | 54 | 0.030 |
Why?
| ortho-Aminobenzoates | 1 | 1993 | 7 | 0.030 |
Why?
| Barium Compounds | 1 | 1993 | 7 | 0.030 |
Why?
| Protein Synthesis Inhibitors | 1 | 2014 | 42 | 0.030 |
Why?
| Chloride Channels | 1 | 1993 | 35 | 0.030 |
Why?
| Fundus Oculi | 1 | 2013 | 40 | 0.030 |
Why?
| Arginine | 1 | 1995 | 236 | 0.030 |
Why?
| Diuretics | 1 | 1993 | 66 | 0.030 |
Why?
| Tenon Capsule | 1 | 2013 | 3 | 0.030 |
Why?
| S-Phase Kinase-Associated Proteins | 1 | 2013 | 18 | 0.030 |
Why?
| Fluorescent Antibody Technique, Indirect | 1 | 2013 | 49 | 0.030 |
Why?
| Ion Channels | 1 | 1993 | 123 | 0.030 |
Why?
| Autophagy | 1 | 2015 | 233 | 0.030 |
Why?
| Lipofuscin | 1 | 2012 | 2 | 0.030 |
Why?
| Pepstatins | 1 | 2012 | 4 | 0.030 |
Why?
| Haplorhini | 1 | 2013 | 57 | 0.030 |
Why?
| beta Catenin | 1 | 2015 | 220 | 0.030 |
Why?
| Cathepsin D | 1 | 2012 | 14 | 0.030 |
Why?
| RNA Interference | 1 | 2015 | 437 | 0.030 |
Why?
| Opsins | 1 | 2012 | 10 | 0.030 |
Why?
| Boron Compounds | 1 | 2012 | 17 | 0.030 |
Why?
| Antibody Formation | 1 | 2014 | 267 | 0.030 |
Why?
| Glaucoma Drainage Implants | 1 | 2013 | 47 | 0.030 |
Why?
| Oxidants | 1 | 2013 | 112 | 0.030 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2013 | 171 | 0.030 |
Why?
| Adult | 4 | 2018 | 30542 | 0.030 |
Why?
| Immunoblotting | 1 | 2012 | 283 | 0.030 |
Why?
| Irritants | 1 | 2012 | 41 | 0.030 |
Why?
| Caspase 3 | 1 | 2013 | 236 | 0.030 |
Why?
| Ubiquitin-Protein Ligases | 1 | 2013 | 139 | 0.020 |
Why?
| Catalytic Domain | 1 | 2012 | 197 | 0.020 |
Why?
| Mechlorethamine | 1 | 2012 | 64 | 0.020 |
Why?
| Homeostasis | 1 | 2015 | 575 | 0.020 |
Why?
| Amino Acid Sequence | 1 | 1996 | 1988 | 0.020 |
Why?
| Brimonidine Tartrate | 1 | 2011 | 9 | 0.020 |
Why?
| Protein Structure, Tertiary | 1 | 2014 | 797 | 0.020 |
Why?
| Rats, Transgenic | 1 | 2011 | 15 | 0.020 |
Why?
| Hydrogen Peroxide | 1 | 2013 | 287 | 0.020 |
Why?
| Desmosterol | 1 | 2011 | 1 | 0.020 |
Why?
| Chemokine CCL2 | 1 | 2011 | 105 | 0.020 |
Why?
| Androstenes | 1 | 2011 | 11 | 0.020 |
Why?
| Cross-Over Studies | 1 | 2013 | 440 | 0.020 |
Why?
| COS Cells | 1 | 2011 | 175 | 0.020 |
Why?
| Laser Coagulation | 1 | 2011 | 54 | 0.020 |
Why?
| Molecular Sequence Data | 1 | 1996 | 2791 | 0.020 |
Why?
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2011 | 20 | 0.020 |
Why?
| Hep G2 Cells | 1 | 2011 | 61 | 0.020 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 1147 | 0.020 |
Why?
| Antibodies, Viral | 1 | 2014 | 521 | 0.020 |
Why?
| Mustard Gas | 1 | 2012 | 117 | 0.020 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2011 | 154 | 0.020 |
Why?
| Young Adult | 2 | 2018 | 10461 | 0.020 |
Why?
| Phosphorylation | 1 | 2015 | 1571 | 0.020 |
Why?
| Intestinal Absorption | 1 | 1991 | 93 | 0.020 |
Why?
| Microscopy, Fluorescence | 1 | 2012 | 398 | 0.020 |
Why?
| Mutagenesis, Site-Directed | 1 | 2011 | 345 | 0.020 |
Why?
| Immunoglobulin G | 1 | 2014 | 774 | 0.020 |
Why?
| Recombinant Proteins | 1 | 2013 | 1233 | 0.020 |
Why?
| Membrane Potentials | 1 | 2010 | 249 | 0.020 |
Why?
| Drug Therapy, Combination | 1 | 2012 | 954 | 0.020 |
Why?
| RNA, Ribosomal, 18S | 1 | 2009 | 21 | 0.020 |
Why?
| Ketorolac | 1 | 2009 | 16 | 0.020 |
Why?
| Gene Amplification | 1 | 2009 | 97 | 0.020 |
Why?
| ATP Binding Cassette Transporter 1 | 1 | 2008 | 10 | 0.020 |
Why?
| Foam Cells | 1 | 2008 | 13 | 0.020 |
Why?
| Mice, Knockout | 1 | 2015 | 2582 | 0.020 |
Why?
| Sterol Regulatory Element Binding Protein 1 | 1 | 2008 | 54 | 0.020 |
Why?
| Feces | 1 | 2011 | 374 | 0.020 |
Why?
| Hypertriglyceridemia | 1 | 2008 | 34 | 0.020 |
Why?
| Fibroblasts | 1 | 2013 | 838 | 0.020 |
Why?
| Polymerase Chain Reaction | 1 | 2011 | 994 | 0.020 |
Why?
| Apolipoproteins E | 1 | 2008 | 80 | 0.020 |
Why?
| DNA Primers | 1 | 2009 | 514 | 0.020 |
Why?
| ATP-Binding Cassette Transporters | 1 | 2008 | 123 | 0.020 |
Why?
| Intestines | 1 | 2011 | 325 | 0.020 |
Why?
| Sodium Hydroxide | 1 | 2007 | 8 | 0.020 |
Why?
| Receptors, Peptide | 1 | 2007 | 18 | 0.020 |
Why?
| Cell Fractionation | 1 | 2007 | 51 | 0.020 |
Why?
| Nerve Tissue Proteins | 1 | 2011 | 529 | 0.020 |
Why?
| Polyethylene Glycols | 1 | 2011 | 561 | 0.020 |
Why?
| Models, Theoretical | 1 | 2010 | 516 | 0.020 |
Why?
| Cytomegalovirus | 1 | 2007 | 144 | 0.020 |
Why?
| Lipopolysaccharides | 1 | 2009 | 812 | 0.020 |
Why?
| Biomedical Research | 1 | 2010 | 585 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2011 | 2537 | 0.010 |
Why?
| Phloretin | 1 | 1996 | 1 | 0.010 |
Why?
| Phlorhizin | 1 | 1996 | 2 | 0.010 |
Why?
| Levobunolol | 1 | 1993 | 1 | 0.010 |
Why?
| Betaxolol | 1 | 1993 | 2 | 0.010 |
Why?
| Atenolol | 1 | 1993 | 6 | 0.010 |
Why?
| Nasolacrimal Duct | 1 | 1993 | 7 | 0.010 |
Why?
| Kinetics | 1 | 1996 | 1550 | 0.010 |
Why?
| Glucose | 1 | 1996 | 897 | 0.010 |
Why?
| Aged | 1 | 2009 | 19078 | 0.010 |
Why?
|
|
Kompella's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|